Futura Medical plc (FAMDF)
USD 0.12
(26.32%)
USD 0.12
(26.32%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.83 Million GBP | 0.19% |
| 2022 | -6.84 Million GBP | -17.11% |
| 2021 | -5.84 Million GBP | -101.37% |
| 2020 | -2.9 Million GBP | 73.94% |
| 2019 | -11.14 Million GBP | -53.77% |
| 2018 | -7.24 Million GBP | -49.65% |
| 2017 | -4.84 Million GBP | -6.48% |
| 2016 | -4.54 Million GBP | 25.57% |
| 2015 | -6.1 Million GBP | -73.46% |
| 2014 | -3.52 Million GBP | -39.34% |
| 2013 | -2.52 Million GBP | -3.02% |
| 2012 | -2.45 Million GBP | -18.48% |
| 2011 | -2.09 Million GBP | -58.21% |
| 2010 | -1.32 Million GBP | 12.79% |
| 2009 | -1.51 Million GBP | 27.21% |
| 2008 | -2.15 Million GBP | 15.77% |
| 2007 | -2.6 Million GBP | -24.77% |
| 2006 | -1.96 Million GBP | 11.22% |
| 2005 | -2.34 Million GBP | -60.26% |
| 2004 | -1.56 Million GBP | 4.7% |
| 2003 | -1.44 Million GBP | -18.41% |
| 2002 | -1.22 Million GBP | 6.86% |
| 2001 | -1.31 Million GBP | -240.78% |
| 2000 | -385 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 439.55 Thousand GBP | 0.0% |
| 2024 Q1 | 439.55 Thousand GBP | 117.8% |
| 2023 Q1 | -946.89 Thousand GBP | 76.38% |
| 2023 Q3 | -2.46 Million GBP | -30.42% |
| 2023 Q4 | -2.46 Million GBP | 0.0% |
| 2023 FY | - GBP | 0.19% |
| 2023 Q2 | -1.89 Million GBP | -100.0% |
| 2022 Q4 | -4 Million GBP | -100.0% |
| 2022 Q2 | -2.83 Million GBP | -100.0% |
| 2022 Q1 | -1.41 Million GBP | 64.14% |
| 2022 FY | - GBP | -17.11% |
| 2022 Q3 | -2 Million GBP | 29.35% |
| 2021 Q3 | -1.97 Million GBP | -4.63% |
| 2021 Q2 | -1.89 Million GBP | -100.0% |
| 2021 FY | - GBP | -101.37% |
| 2021 Q1 | -945.21 Thousand GBP | 37.93% |
| 2021 Q4 | -3.95 Million GBP | -100.0% |
| 2020 Q2 | -1.38 Million GBP | -100.0% |
| 2020 Q3 | -761.43 Thousand GBP | 44.84% |
| 2020 FY | - GBP | 73.94% |
| 2020 Q4 | -1.52 Million GBP | -100.0% |
| 2020 Q1 | -690.25 Thousand GBP | 88.25% |
| 2019 Q3 | -2.93 Million GBP | 44.21% |
| 2019 FY | - GBP | -53.77% |
| 2019 Q1 | -2.63 Million GBP | -11.16% |
| 2019 Q2 | -5.26 Million GBP | -100.0% |
| 2019 Q4 | -5.87 Million GBP | -100.0% |
| 2018 Q3 | -2.36 Million GBP | -88.86% |
| 2018 FY | - GBP | -49.65% |
| 2018 Q2 | -1.25 Million GBP | -0.0% |
| 2018 Q1 | -1.25 Million GBP | 11.33% |
| 2018 Q4 | -2.36 Million GBP | 0.0% |
| 2017 Q2 | -1 Million GBP | 0.0% |
| 2017 Q1 | -1 Million GBP | 12.25% |
| 2017 Q4 | -1.41 Million GBP | 0.0% |
| 2017 FY | - GBP | -6.48% |
| 2017 Q3 | -1.41 Million GBP | -41.17% |
| 2016 Q1 | -1.13 Million GBP | 26.76% |
| 2016 FY | - GBP | 25.57% |
| 2016 Q3 | -1.14 Million GBP | -0.88% |
| 2016 Q2 | -1.13 Million GBP | 0.0% |
| 2016 Q4 | -1.14 Million GBP | 0.0% |
| 2015 Q1 | -1.5 Million GBP | -61.21% |
| 2015 Q2 | -1.5 Million GBP | 0.0% |
| 2015 Q4 | -1.54 Million GBP | 0.0% |
| 2015 Q3 | -1.54 Million GBP | -2.39% |
| 2015 FY | - GBP | -73.46% |
| 2014 Q2 | -824.83 Thousand GBP | -0.0% |
| 2014 Q3 | -936.31 Thousand GBP | -13.52% |
| 2014 FY | - GBP | -39.34% |
| 2014 Q4 | -936.31 Thousand GBP | 0.0% |
| 2014 Q1 | -824.83 Thousand GBP | -10.59% |
| 2013 Q3 | -745.87 Thousand GBP | -43.99% |
| 2013 Q2 | -518 Thousand GBP | 0.0% |
| 2013 Q1 | -518 Thousand GBP | 0.0% |
| 2013 FY | - GBP | -3.02% |
| 2013 Q4 | -745.87 Thousand GBP | 0.0% |
| 2012 FY | - GBP | -18.48% |
| 2011 FY | - GBP | -58.21% |
| 2010 FY | - GBP | 12.79% |
| 2009 FY | - GBP | 27.21% |
| 2008 FY | - GBP | 15.77% |
| 2007 FY | - GBP | -24.77% |
| 2006 FY | - GBP | 11.22% |
| 2005 FY | - GBP | -60.26% |
| 2004 FY | - GBP | 4.7% |
| 2003 FY | - GBP | -18.41% |
| 2002 FY | - GBP | 6.86% |
| 2001 FY | - GBP | -240.78% |
| 2000 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | -78.88% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 90.38% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -2757.411% |
| SQZ Biotechnologies Company | -64.14 Million USD | 89.346% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -158.409% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 60.659% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 107.267% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -344.875% |
| Marizyme, Inc. | -34.28 Million USD | 80.066% |
| Genus plc | 73.7 Million USD | 109.272% |
| Pharming Group N.V. | 9.87 Million USD | 169.186% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -359.422% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -92.656% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 22.099% |
| ContraFect Corporation | -64.99 Million USD | 89.487% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -387.477% |
| IMV Inc. | -35.52 Million USD | 80.763% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -194.063% |
| ONE Bio Corp. | 13.61 Million USD | 150.198% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 85.831% |
| Mesoblast Limited | -62.38 Million USD | 89.047% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1219.091% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 291.307% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.253% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -980.556% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -199.126% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -15.257% |
| Biomind Labs Inc. | -1.03 Million USD | -560.529% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -136.263% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 4.577% |
| Skye Bioscience, Inc. | -13.54 Million USD | 49.559% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 101728.465% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -3.357% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -27233.992% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -50.977% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -75.925% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 56.94% |
| Accustem Sciences Inc. | -3.74 Million USD | -82.401% |
| EV Biologics, Inc. | -1.26 Million USD | -439.289% |
| Q BioMed Inc. | -617.62 Thousand USD | -1006.41% |
| GB Sciences, Inc. | -1.41 Million USD | -381.271% |
| Alpha Cognition Inc. | -9.7 Million USD | 29.592% |
| CSL Limited | 4.78 Billion USD | 100.143% |
| Agentix Corp. | -1.37 Million USD | -398.157% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 82.76% |
| Enzolytics Inc. | -2.12 Million USD | -222.027% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -11.74 Million USD | 41.803% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -123.097% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -173.126% |
| argenx SE | -216.02 Million USD | 96.837% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 87.652% |
| HST Global, Inc. | -5303.00 USD | -128760.984% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 661.504% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -232.207% |
| Halberd Corporation | -74.27 Thousand USD | -9099.771% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 177.182% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1903.776% |
| Zenith Capital Corp. | -8.6 Million USD | 20.596% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -355.899% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -179.322% |
| AVAX Technologies, Inc. | -6.11 Million USD | -11.793% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -3782.132% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -255.743% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -39125.636% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -560.371% |
| Helix BioMedix, Inc. | -1.04 Million USD | -553.103% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -290.486% |
| Kadimastem Ltd | -2.62 Million USD | -160.385% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 9.534% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -3673.579% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 1757.478% |
| Cell Source, Inc. | -4.27 Million USD | -59.94% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1760.868% |
| Regen BioPharma, Inc. | 1.46 Million USD | 566.146% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -629.335% |
| Affymax, Inc. | -14.29 Million USD | 52.197% |
| Mobile Lads Corp. | -2.24 Million USD | -204.909% |
| Itoco Inc. | -1.86 Million USD | -265.624% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1700.089% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -512.321% |
| International Stem Cell Corporation | 202 Thousand USD | 3482.92% |
| CytoDyn Inc. | -18.02 Million USD | 62.097% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -8546.823% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -55779.45% |
| Qrons Inc. | -40.08 Thousand USD | -16949.22% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1307.002% |
| SYBLEU INC | -141.57 Thousand USD | -4726.905% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1395.614% |
| Rebus Holdings, Inc. | -951 Thousand USD | -618.559% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -543.449% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -12881.569% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -177.566% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 80.949% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -15085.551% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -149.58% |
| Neutra Corp. | -181.24 Thousand USD | -3670.268% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 66.102% |
| PureTech Health plc | -11.62 Million USD | 41.227% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 66.1% |
| IXICO plc | -707 Thousand USD | -866.549% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 11.08% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 85.865% |
| CSL Limited | 4.73 Billion USD | 100.144% |
| Cellectis S.A. | -92.63 Million USD | 92.623% |